This cluster groups 2 independently calculated changes: Cash & equivalents increased 25.8%; Operating cash flow increased 26.1%.
2 evidence-backed components· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOTenGene Therapeutics Inc.'s latest supported as-filed period reports net income of -$32.5M. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Cash & equivalents increased 25.8%; Operating cash flow increased 26.1%.
2 evidence-backed componentsThis cluster groups 2 independently calculated changes: Cash & equivalents decreased 48.2%; Operating cash flow decreased 32.9%.
2 evidence-backed componentsFree-cash-flow proxy changed +28.1% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Each point keeps the date investors could first observe it and its accession.
ENGN · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-384383SEC ↗8-KSep 8, 2026Period Sep 8, 20260001193125-26-384380SEC ↗8-KAug 11, 2026Period Aug 11, 20260001193125-26-344559SEC ↗8-KJul 17, 2026Period Jul 17, 20260001193125-26-307795SEC ↗8-KJul 16, 2026Period Jul 15, 20260001193125-26-305418SEC ↗8-K/AJun 18, 2026Period Jun 16, 20260001193125-26-275815SEC ↗4Jun 17, 2026Period Jun 16, 20260000929638-26-002263SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jun 16, 2026Filed Jun 17, 2026 | Astley-Sparke PhilipDirector | Grant Or AwardDirect | 31,000 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Free-cash-flow proxy changed -33.1% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Operating cash flow changed +26.1% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Operating cash flow changed -32.9% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Shares outstanding changed +31.1% from the comparable as-filed period. The change ranks at the 38th percentile of 8 prior comparable changes.
Shares outstanding changed +30.9% from the comparable as-filed period. The change ranks at the 25th percentile of 8 prior comparable changes.
Capital expenditure changed -100.0% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-07-31. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0000929638-26-002262